Kumagai et al. (14) measured serum CHI3L1 levels in 111 patients with NAFLD and 23 patients with HCC combined with NAFLD and found that serum CHI3L1 levels in patients with NAFLD increased with the progression of hepatic fibrosis. This evidence concerns the gene CHI3L1 and metabolic dysfunction-associated steatotic liver disease.